A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea

BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in S...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Medicine (Baltimore)
Κύριοι συγγραφείς: Lee, Hee Seung, Chung, Moon Jae, Park, Jeong Youp, Bang, Seungmin, Park, Seung Woo, Kim, Ho Gak, Noh, Myung Hwan, Lee, Sang Hyub, Kim, Yong-Tae, Kim, Hyo Jung, Kim, Chang Duck, Lee, Dong Ki, Cho, Kwang Bum, Cho, Chang Min, Moon, Jong Ho, Kim, Dong Uk, Kang, Dae Hwan, Cheon, Young Koog, Choi, Ho Soon, Kim, Tae Hyeon, Kim, Jae Kwang, Moon, Jieun, Shin, Hye Jung, Song, Si Young
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Wolters Kluwer Health 2017
Θέματα:
4500
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5228666/
https://ncbi.nlm.nih.gov/pubmed/28072706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005702
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια